response

Heartwarming Global Response to Player Registration for Inaugural Canada Super 60 League

Thursday 17 April, 2025 Ontario, Canada – April 1, 2025 The Canada Super 60 Ten Over Format League has gained…

3 months ago

GW Instek Unveils Full Smart Measurement Portfolio to Accelerate Next-Gen Industrial Testing

TAIPEI, July 8, 2025 /PRNewswire/ -- In response to the global surge in industrial automation and smart manufacturing, precision data…

3 months ago

Marathon Nextgen Realty Raises Rs. 900 Crore Through Qualified Institutions Placement

Overwhelming Response from Premier Domestic and International Institutional Investors Validates Company's Growth Strategy MUMBAI, India, July 4, 2025 /PRNewswire/ --…

3 months ago

Big Bang Boom Solutions Accelerates Deployment of the Indigenous Vajra Sentinel System to the Indian Air Force in Response to Operation Sindoor

Big Bang Boom Solutions (BBBS) announced the successful delivery of the first lot of its Vajra Sentinel Systems, a next-generation…

4 months ago

New Glassnode Report: How Bybit’s Response to the Lazarus Hack Became Crypto’s Defining Stress Test

DUBAI, UAE, July 1, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, has been featured in a…

4 months ago

Vehere Appoints Gulf Software Distribution to Accelerate Market Growth Across the Region

DUBAI, UAE, July 1, 2025 /PRNewswire/ -- Vehere, a new-age cyber defense software company, has engaged Gulf Software Distribution (GSD),…

4 months ago

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…

4 months ago

Investigational combination of first-in-class bispecific antibodies TALVEY (talquetamab) and TECVAYLI (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…

4 months ago

Positive Late-Breaking Data for Incytes First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy…

4 months ago

Prime Success Responds to Sinovac Biotechs False and Misleading Claims

For More Information, Visit www.SaveSinovac.comHONG KONG--(BUSINESS WIRE)--Prime Success L.P., (together with its affiliates, “Prime Success” or “we”), a significant shareholder…

4 months ago